Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Revenue

For the years ended December 31, 2023, 2022 and 2021, revenue comprised the following:

	Year Ended December 31,
(in thousands)	2023		2022		2021
Prescription transactions revenue	$	550,738	$	550,536	$	593,359
Subscription revenue	94,410		96,167		59,925
Pharma manufacturer solutions revenue (1)	85,065		99,425		73,348
Other revenue	20,052		20,426		18,792
Total revenue	$	750,265	$	766,554	$	745,424

_____________________________________________________

(1)Pharma manufacturer solutions revenue for the year ended December 31, 2023 included a $10.0 million contract termination payment to a pharma manufacturer solutions client in connection with our restructuring activities, which was recognized as a reduction of revenue. See "Note 17. Restructuring Plan" for additional information.